Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenue	$ 153,612	$ 147,588	$ 132,257
Cost of goods sold	51,821	41,801	32,750
Gross profit	101,791	105,787	99,507
Operating expenses:
Research and development	26,421	21,616	16,199
Clinical and regulatory affairs	15,418	13,243	8,679
Marketing and sales	78,213	73,411	63,588
General and administrative	29,581	26,663	21,409
Contract termination and business acquisition expenses	5,071	0	0
Total operating expenses	154,704	134,933	109,875
Loss from operations	(52,913)	(29,146)	(10,368)
Other income (expense):
Interest income	175	245	50
Interest expense	(7,476)	(5,709)	(321)
Other income (expense), net	553	(5,798)	3,061
Change in fair value of contingent consideration related to acquisition	(100)	7,928	(8,500)
Total other income (expense)	(6,848)	(3,334)	(5,710)
Net loss before income tax	(59,761)	(32,480)	(16,078)
Income tax benefit	9,337	62	10
Net loss	(50,424)	(32,418)	(16,068)
Other comprehensive income (loss) foreign currency translation	(1,762)	3,369	(845)
Comprehensive loss	$ (52,186)	$ (29,049)	$ (16,913)
Basic and diluted net loss per share (in USD per share)	$ (0.75)	$ (0.50)	$ (0.26)
Shares used in computing basic and diluted net loss per share	67,671	65,225	62,607